AML patient-derived xenograft cells derived from a hyperleukocytic AML-M5 patient with NPM1 and DNMT3A mutations were intravenously injected administered the polysaccharide B-NSG mice and intraperitoneally administered the polysaccharide nanotube containing selenium nanoparticles (0.05 mg/kg) [170]. The gene discussed is DNMT3A; the disease is acute myeloid leukemia.